The Evidence Ledger
← The Evidence Ledger

Mebendazole

MechanismPLAUSIBLEOutcomeC
Claimed

The human anti-parasitic cousin of fenbendazole disrupts microtubules in dividing cancer cells and crosses into the brain.

What holds up

Microtubule disruption mechanism, human trials exist unlike most benzimidazoles.

What it does not show

Multiple phase 1/2a trials always added to chemo; built for dose and safety, not to prove benefit.

Evidence for

Gallia et al., Neuro-Oncology Advances 2021;3(1):vdaa154, Kars et al., Cancer Medicine 2020, DOI 10.1002/cam4.3094, Mansoori et al., Scientific Reports 2021, Hegazy et al., Life Sciences 2022 (often miscited as 'Touti'), Nygren and Larsson, Acta Oncologica 2014, a case report, not a trial

Sources

VERIFIED Gallia et al., Neuro-Oncology Advances 2021;3(1):vdaa154. VERIFIED Kars et al., Cancer Medicine 2020, DOI 10.1002/cam4.3094. VERIFIED Mansoori et al., Scientific Reports 2021. VERIFIED Hegazy et al., Life Sciences 2022 (often miscited as 'Touti'). VERIFIED Nygren and Larsson, Acta Oncologica 2014, a case report, not a trial.

Grade history (append-only)

Every grade change is kept, never overwritten, so the current grade and every prior one stay visible.

Mechanism gradeJustificationGraded byStateGraded at
PLAUSIBLEMicrotubule disruption mechanism, human trials exist unlike most benzimidazoles.seeddisplayed2026-09-03T21:29:06.023Z
Outcome gradeJustificationGraded byStateGraded at
CMultiple phase 1/2a trials always added to chemo; built for dose and safety, not to prove benefit.seeddisplayed2026-09-03T21:29:06.023Z

Submit evidence for or against this claim